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ABSTRACT The mutant p21ras protein is a G protein produced by the point-mutated H-ras gene, and this mutant protein has
been shown to cause carcinogenesis due to a reduction in its GTPase activity. However, the mechanism underlying this
strange phenomenon has still not been elucidated. In our previous study, we have clarified the mechanism of the GTP3GDP
hydrolysis reaction in the wild-type p21ras at the atomic level and concluded that GTPase-activating protein plays a significant
role in the supply of H2O molecules for the hydrolysis. The structure of the active site in the mutant is the same as that in the
wild type. However, by performing molecular dynamic calculations, we found that the structure of the active site of the
enzyme substrate complex in the oncogenic mutant p21ras continuously changes, and these continuous changes in the active
site would make it difficult for the GTP3GDP hydrolysis reaction to occur in the mutant. These findings can explain the fact
that the GTPase activity in the mutant was only 15% of that in the wild type and the fact that GTPase-activating protein has
no reaction-activating effect in the mutant. This is a dynamic inhibition mechanism of a vital reaction that can be explained
by considering the molecular dynamics.
INTRODUCTION
The c-Ha-ras gene (Shih et al., 1979) produces the small
GTP-binding protein p21ras. p21ras is thought to play an
important role in intracellular signal cascades in mammals.
It has also been shown that p21ras, which is a G protein, is
active when GTP is bound to it but becomes inactive when
GTP is hydrolyzed to GDP and inorganic phosphoric acid
(Maegley et al., 1996). This transformation from being
active with GTP to inactive with GDP is the molecular
switching mechanism of p21ras (Barbacid, 1987; Lim et al.,
1996; Milburn et al., 1990).
It is known that carcinogenesis is caused by the mutant
p21ras substituting only an amino acid Gly-12 in the wild
type to another amino acid, such as Val-12 (except Pro-12)
coded by the mutant ras gene, or, in other words, the ras
oncogene. It has also been experimentally shown that
GTPase activity in p21ras is reduced by the same substitu-
tion of Gly12 by other amino acids (except Pro-12) (Chung
et al., 1993). Unless GTP3GDP hydrolysis occurs regu-
larly, most of the p21ras protein retains active conformation
with GTP. The cause of carcinogenesis is thought to be an
excessive induction of intracellular signal cascades due to
an undesirable increase of the active conformation (Bar-
bacid, 1987).
Because the difference between the wild-type p21ras and
the oncogenic mutant p21ras originates from the capability
of GTP3GDP hydrolysis, we investigated the mechanism
by which GTP3GDP hydrolysis occurs in the wild-type
p21ras.
It was found, using ab initio calculations, that the proton
relay reaction via -nitrogen of the side chain of Lys-16
(Lys-16-N) played an important role in the mechanism of
hydrolysis (Futatsugi et al., 1997, 1999). Details are shown
in Fig. 1. However the amino acid (position 12) that caused
carcinogenesis is not included in the structure of the active
site for the proton relay via Lys-16. Therefore, molecular
dynamics calculations were performed on the wild-type
p21ras, the Gly-123Val oncogenic mutant p21ras, and the
Gly-123Pro nononcogenic mutant p21ras.
MATERIALS AND METHODS
AMBER with high-speed accelerator
MD simulations were performed on Sun SparkStation5 with the hardware
accelerator called MD-Engine (Toyoda et al., 1995, 1999), using the
AMBER version 4.0 software package from University of California at San
Francisco (Pearlman et al., 1995).
The MD-Engine is able to calculate nonboned interactions at high
speed, such as Coulomb or van der Waals interactions. Therefore, this
hardware can calculate without cutoff technique, which produced some
errors in the results of MD simulations and can restrain artificial behavior
by errors.
Minimization and molecular dynamics
The structural model of the wild-type p21ras is 121p in the protein data
bank (Abola et al., 1987) data, using the nonhydrolyzed analog (guanosine-
5-[,-methylene] triphosphate) in place of the GTP. The MD simulation
software package AMBER was used for calculations, using the parm94
force field (Cornel et al., 1995). We created the force field and charges for
GTP and Mg2 in p21ras using Gaussian 94 (Frisch et al., 1995a,b).
Calculations were performed in the Hartree-Fock level, using a basis
functional set, 6-31G**. The structures of GTP and Mg2 were optimized
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and decided charges in atoms and then the force field was produced using
these charges by the PREP program in the AMBER.
To mimic aqueous solvent conditions, 2800 solvent water mole-
cules (TIP3P water model) were created using the Monte Carlo method,
as the whole enzyme was enveloped by a water layer of 30 Å in radius.
The whole structure including solvent waters was energy minimized.
First, the temperature was gradually increased to 300 K for 104 ps,
and then the kinetic energy for MD simulation was provided by a
thermal bath at a constant temperature required for vital body condi-
tions, 300 to 310 K, for 1000 ps (5000 steps of 2.0 fs each) using
SHAKE method. Nonbonded interactions were evaluated without a
cutoff distance using the MD-Engine. The simulation outputted data
occurring every 100 fs during the trajectory and stored as a history file.
The oncogenic mutant (Gly-12-Val; 521p) (Pai et al., 1989, 1990) and
the nononcogenic mutant (Gly-12-Pro; 821p) (Krengel et al., 1990;
Scheidig et al., 1992; Pai et al., 1990) were also calculated by the same
procedure as that used for the wild-type p21ras.
RESULTS AND DISCUSSION
Dynamic inhibition mechanism
The results showed that there is a clear difference in terms
of time between the structures of the active sites of the wild
type and mutants. The following is explanation for the
results using figures and these picked up structures at 700 ps
with clear differences between the wild type and mutants.
Fig. 2 shows the changes in function time in the structure of
the active site of the wild-type p21ras and, as one example,
the structure of the active site of the wild type at 700 ps. As
can be seen in these figures, the active site of the wild-type
p21ras maintains a regular structure with few changes. How-
ever, the oncogenic mutant p21ras showed quite different
changes in function time in its structure. Fig. 3 shows
changes in function time in the structure of the Gly-
123Val oncogenic mutant p21ras and one example of the
structure of this mutant. The results for the Gly-123Pro
nononcogenic mutant p21ras are shown in Fig. 4. Certainly,
FIGURE 1 GTP3GDP hydrolysis reaction in the wild-type p21ras.
First, a water molecule coordinates to -phosphate (1). Next, a proton
binding to the oxygen of -phosphate moves to Lys-16-N (a), and a proton
of the water molecule moves to the oxygen of -phosphate (b). Next,
another proton of Lys-16-N moves to the oxygen of -phosphate (c), and
the bond distance between -phosphate and -phosphate is extended (2).
Eventually, GTP is dissociated into GDP and a phosphate.
FIGURE 2 Results of molecular dynamics calculation for the wild-type p21ras. The abscissa indicates time (ps) for molecular dynamics, and the ordinate
indicates distances (Å) among atoms in the active site of p21ras. Both the distances between Lys-16-N and the oxygen of -phosphate (N-O1) and between
Lys-16-N and the oxygen of -phosphate (N-O1) remain constant at 3 Å. The distances between Mg and the oxygen of -phosphate (Mg-O2) and between
Mg and the oxygen of -phosphate (Mg-O2) also remain constant at 2 Å. The structure shown is an example of the wild-type p21ras at 700 ps (Å).
3484 Futatsugi and Tsuda
Biophysical Journal 81(6) 3483–3488
it seems that the nononcogenic mutant fulfills its mecha-
nism in the same manner as does the wild type, because
changes in function time in the active site structure of the
nononcogenic mutant are very similar to those in the wild
type. According to these figures, the distance between Lys-
16-N and -phosphate in the oncogenic mutant p21ras fluc-
tuates between 3 and 5 Å, thereby changing the active
structure for hydrolysis of the enzyme.
FIGURE 3 Results of molecular dynamics calculation for the Gly-123Val oncogenic mutant p21ras. The abscissa indicates time (ps) for molecular
dynamics and the ordinate indicates distances (Å) among atoms in the active site of p21ras. The distance between Lys-16-N and the oxygen of -phosphate
(N-O1) remains at 3 Å, but the distance between Lys-16-N and the oxygen of -phosphate (N-O1) fluctuates irregularly. Mg holds GTP as it does
in the wild-type p21ras. The structure shown is an example of the Gly123Val oncogenic mutant p21ras at 700 ps (Å). The distance between Lys-16-N and
the oxygen of -phosphate (N-O1) has been expanded from 2.88 Å in the normal structure (Fig. 2) to 4.82 Å, and Lys-16-N approaches the oxygen
coordinating to Mg instead of the oxygen of -phosphate (O2) (4.92 Å 3 2.74 Å).
FIGURE 4 Results of molecular dynamics calculation for the Gly-123Pro nononcogenic mutant p21ras. The abscissa indicates time (ps) for molecular
dynamics and the ordinate indicates distances (Å) among atoms in the active site of p21ras. These results are very similar to those for the wild type. The
structure shown is an example of the Gly-123Pro nononcogenic mutant p21ras at 700 ps (Å).
Dynamic Inhibition Mechanism 3485
Biophysical Journal 81(6) 3483–3488
Thus, the spatial position of Lys-16 in the active site of
the oncogenic mutant p21ras is unstable, and the active site
structure of enzyme substrate (ES) complex is broken and
later restored. This suggests that the GTP3GDP hydrolysis
reaction shown in Fig. 1 rarely occurs in the oncogenic
mutant p21ras. The GTPase activity in the Gly-123Val
mutant p21ras remains at 15% (Chung et al., 1993) be-
cause, as shown in Fig. 3, the proton relay reaction occurs
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FIGURE 5 In the Gly-123Val mutant p21ras, the structures at: 200 ps (normal), 300 ps (change), 400 ps (normal), and 700 ps (change) are shown. The
relative position between the side chain of Val-12 (C-C) and the main chain of Lys-16 (C-N) (light blue lines) is shown with dihedral angles: 87.6°
at 200 ps and 81.9° at 400 ps in the normal period, but 133.9° at 300 ps and 117.7° at 700 ps in the period of change. The side chain of Val-12 rotated
perpendicularly to the loop structure constructed with the main chain of the peptide and the side chain of Lys-16. Consequently, the distance between the
nitrogen of the side chain of Lys-16 (N) and the oxygen of -phosphate (O1) maintains a hydrogen bond in the normal period but extends in the period
of change and N of Lys-16 exchange the bond with O2 of -phosphate instead of O1. The structural differences among the structures in the normal
period and the period of change are shown by red lines; i.e., the direction of the side chain of Val-12 (C1-C-C2), the positions of C and C of the main
chain of Val-13, and the relative positions between C of Gly-15 and N of Ser-17 were confirmed.
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while the hydrogen bond between Lys-16-N and the oxygen
of -phosphate is kept at a distance of 3 Å.
Because the crystal structure of the ES complex of the
Gly-123Val mutant p21ras determined by x-ray analysis is
not different from that of the wild-type p21ras, this blocking
mechanism of enzyme activity was determined by molecu-
lar dynamics. For this reason, this blocking mechanism
could be termed a “dynamic inhibition mechanism.”
The GTP hydrolysis ability of p21ras is enhanced by creat-
ing a complex with Ras-GTPase-activating protein (p120-
GAP) (Ahmadian et al., 1997; Boguski andMcCormick, 1993;
Giglione et al., 1997) and the Gly-123Val oncogenic mutant
p21ras binds to GTPase-activating protein (GAP) with an af-
finity similar to that of the wild type (Gideon et al., 1992).
However, GAP-accelerated GTP hydrolysis is blocked in the
case of the Gly-123Val mutant p21ras. Scheffzek et al. (1997)
analyzed the crystal structure of the Ras-RasGAP complex and
discussed the effect of the mutation of residue 12, and then
they described “the closest encounter being a van der Waals
contact between the C atom of Gly-12 and the mode of
interaction imposes constraints on the space that may be filled
by amino acids in position 12 of Ras and provides an expla-
nation for the block in GAP-accelerated GTP hydrolysis.”
However we consider that reduction of GTPase activity have
other main origin of the blocking involved directly reaction in
the active site, and this is not able to be seen on the static x-ray
crystal structure. The Gly-123Val oncogenic mutant p21ras
has a similar structure in the active site to that of the wild type
and the Gly-123Pro nononcogenic mutant, and the crystal
structures are almost the same. Thus, the difference in action
between the wild type and the Gly-12 mutant p21ras cannot be
found by studying only the static structures. In the present
study, we showed, using a dynamic method, that there are
changes in function time in the active site originating from the
substitution of Gly-12 by another amino acid, and we suc-
ceeded to clarify the origin of the carcinogenesis caused by a
point mutation.
How does the dynamic inhibition
mechanism operate?
Fig. 5 shows the structures determined by MD calculations
at 200 ps (normal), 300 ps (change), 400 ps (normal), and
700 ps (change), respectively, in the Gly-123Val mutant
p21ras. “Normal” means that the structure of the active site
keeps a hydrogen bond between the Lys-16-N and the
oxygen of the -phosphate. “Change” means the structure of
the active site does not keep a hydrogen bond. To clarify the
characteristics of the structures, the main chain of the pep-
tide with the side chain of Lys-16 is shown in each of the
four structures in Fig. 6. It is clear from Fig. 6 that the
structures at 200 ps and the 400 ps in the normal period, as
well as structures at 300 ps and the 700 ps in the period of
change are very similar in each group, but the structures
between these two groups are very different. To investigate
the origin of the difference, the relative position between the
C-C bond of the side chain of Val-12 and the C-N bond
of the main chain of Lys-16 (light blue lines in Fig. 5) was
measured with respect to the dihedral angles, and large
differences in angle were found among these structures in
the normal period and the period of change; i.e., 87.6° at
200 ps and 81.9° at 400 ps in the normal period, on the other
hand, 133.9° at 300 ps and 117.7° at 700 ps in the period of
change. This result shows that the side chain of Val-12
rotates perpendicularly with respect to the plane of the loop
structure constructed with Ala-11, Val-12, Gly-13, Val-14,
Gly-15, and Lys-16. Consequently, the relative positions of
C and C (red line in Fig. 5) of Gly-13 were different in the
two groups; i.e., C turned down to the position of C in the
normal period but turned up to C at almost the same height
in the period of change. In addition to this change, we found
that the positions between Gly-15 and Ser-17 (red line in
Fig. 5) were different across the main chain of Lys-16 in the
period of change as compared with the structures in the
normal period. On the structure of Lys-16, the positions of
C, C, C, and N are very different in the two groups. For
this reason, the distance between N of Lys-16 and O1 of
-phosphate keeps a hydrogen bond in the normal period
but no hydrogen bond in the period of change. And, the
distance between N of Lys-16 and O2 of -phosphate
forms a hydrogen bond in the latter. That is, because the
side chain of Val-12 sways perpendicularly to the plane
constructed by the main chain of the peptide and the side
chain of Lys-16, this sway is the trigger to change the
position of the side chain of Lys-16 to produce two kinds of
300ps (changed)
700ps (changed)
200ps (normal)
400ps (normal)
FIGURE 6 In the Gly-123Val mutant p21ras, the structures at 200 ps
(red) and 400 ps (pink) in the normal period as well as the structures at 300
ps (blue) and 700 ps (light blue) in the period of change are very similar in
each group for Ala-11 through Ser-17 in the loop structure, but structures
between these two groups are very different.
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hydrogen bond; i.e., a hydrogen bond between N of Lys-16
and O1 of -phosphate or that of N and O2.
The wild-type p21ras with Gly-12, however, differs from
the case of Val-12 because Gly-12 has no side chain and
does not trigger by the sway of the side chain to the loop
structure constructed with the main chain of the peptide and
the side chain of Lys-16. The Gly-123Pro nononcogenic
mutant p21ras increases the stability of the loop structure
because the circular structure of the main chain arising from
Pro, which has no side chain, cannot trigger by the sway.
Therefore, we conclude that the origin of the dynamic inhi-
bition mechanism is the instability of the position of Lys-16-N,
which is brought about by the force to the main chain of the
peptide caused by sway of the side chain of Val-12.
CONCLUSIONS
The stability of the spatial position of Lys-16, which plays
a central role in the mechanism of the GTP3GDP hydro-
lysis reaction, fluctuates in the Gly-12 mutant p21ras, which
is created by the H-ras oncogene. Thus, in the wild-type and
the nononcogenic mutant p21ras, the structure of the active
site for the GTP3GDP hydrolysis reaction remains intact
under vital body conditions, but in the oncogenic mutant
p21ras, the distance between Lys-16-N and -phosphate
continuously changes time after time, destroying the struc-
ture of the ES complex and thereby making it very difficult
for the GTP3GDP hydrolysis reaction to occur. This dem-
onstrates the existence of a new mechanism for dynamic
inhibition of a vital reaction. The point-mutated H-ras acts
as an oncogene by coding the Gly-12 mutant p21ras with
this dynamic inhibition mechanism.
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